Replies to post #88900 on Biotech Values

[turtlepower]

IDIX - Since cash is adequate for less than a full year do you see them do a financing deal if they don't ink a deal for 184 by the 1st Q?

[DewDiligence]

IDIX update from JPM: Contrary to what I previously posted, IDX320 is not the same drug as IDX316; rather, IDX320 is a more potent protease inhibitor with the same macrocyclic structure.

While IDIX was talking about IDX316 to investors last year, IDX320 was lurking as the backup compound. Perhaps IDIX never mentioned IDX320 to investors until this week to keep the competition off guard.

JP Sommadossi expects IDX320 to be effective at a daily dose* of only 50-400mg. By comparison, the daily doses of Telaprevir and Boceprevir are 2250mg and 2400mg, respectively.

I’ll post more notes on the JPM webcast later.

*qD vs BID dosing is to be determined; the half-life is 8-10 hours.

[DewDiligence]

IDIX 2010 Possible/Probable News Flow

[Updated for 1/14/10 JPM webcast.]


HCV

Any day: Start phase-1 trial for IDX320 protease inhibitor. (A CTA, the European equivalent of an IND, was submitted in 4Q09.)

Apr 2010 at EASL: Report additional phase-2a data for IDX184 nucleotide polymerase inhibitor. (Interim data from the 50mg qD cohort were reported on 1/11/10.)

Apr 2010 at EASL: Report additional phase-1 data for IDX375 non-nucleoside polymerase inhibitor. (Interim data were reported on 1/11/10.)

Timing uncertain (likely 1H10): Ink IDX184 partnership.

Mid 2010: Start phase-1/2 PoC study for IDX375.

Mid 2010: Start phase-1/2 PoC study for IDX320.

Nov 2010 at AASLD: Present complete phase-2 data for IDX184.

2H10: Select lead compound for NS5A program. Start phase-1 in 1H11.


HIV

Mar 2010: GSK* completes IDX899 PK/food study testing multiple formulations at 100mg qD (#msg-44790049).

2Q10: Start phase-2b trials of IDX899 in treatment-naïve and treatment-experienced settings using the preferred 100mg formulation from the PK/food study.

*GSK is the operator of ViiV Healthcare, the joint venture with PFE that is the licensee of IDX899 (#msg-43254006).